kringle-pharmaCo., Ltd.

Kringle Pharma is a late clinical-stage biopharmaceutical company

aiming to provide new medicines to patients and bring
a smile to people’s faces.

NEWS

notice

Jun 14, 2021 Notice
It is an honor to announce that Dr. Kazuya Kitamura of Keio University School of Medicine / National Defense Medical College, Japan, was awarded the APSS CONGRESS Best Clinical Research Award at the 13th Combined Meeting of Asia Pacific Spine Society & Asia Pacific Paediatric Orthopaedic Society (APSS-APPOS 2021), which was held from June 9 to 12, 2021 at Kobe International Conference Center, Kobe City, Japan. Dr. Kitamura presented positive results from the Phase I/II clinical study in patients with acute spinal cord injury, entitled “Intrathecal administration of recombinant human hepatocyte growth factor for acute traumatic cervical spinal cord injury: double-blinded, placebo-controlled and randomized phase I/II study”.
Mar 08, 2021 Notice
Kringle Pharma today announces the addition of two clinical trial sites for Phase 3 of recombinant human HGF (KP-100IT) in acute spinal cord injury. The newly added sites are Japanese Red Cross Kobe Hospital as an acute care hospital and Aijinkai Rehabilitation Hospital as a convalescent rehabilitation hospital. New clinical sites expand opportunities for subject enrollment and confirming clinical feasibility of the KP-100IT therapy by a combination of the acute care and rehabilitation hospitals. Currently, five clinical sites including three national spinal cord injury centers are active for the ongoing Phase 3 trial in Japan. Detailed information about this Phase 3 trial is available at ClinicalTrials.gov using the identifier NCT04475224.

OUR BUSINESS

Research and Development

We will contribute to our society and global health by research,
development and commercialization of innovative medicines for patients suffering from incurable diseases.

Kringle Pharma is a late clinical-stage biopharmaceutical company.
Currently, we are conducting clinical trials of HGF protein, which is a regenerative drug candidate, for the treatment of rare and intractable diseases.
Our strength is that we have a proprietary platform for manufacturing HGF protein in pharmaceutical grade. While maintaining the basic policy of in-house development and sales model, we will build a unique business model that combines out-licensing, co-development and API supply models to maximize profits over the medium to long term.

COMPANY

Corporate information